Yükleniyor...
Radar Rating
Average
5-dimension analyst performance assessment
Total Analyses
20
Buy
13
Sell
7
Hold
0
Unique Assets
10
Active Days
127+
The speaker addresses the sharp decline in Elevance Health shares and the environment of uncertainty created by the Medicare proposal.
* Does not constitute investment advice
The speaker comments on the selling pressure on Centene and future expectations resulting from the policy change in the health insurance sector.
* Does not constitute investment advice
The speaker examines the regulatory news leading to the worst day in a decade for CVS shares and its medium-term implications.
* Does not constitute investment advice
The speaker analyzes the sharp decline in Humana shares caused by the new health policy proposal and the pessimistic outlook across the sector.
* Does not constitute investment advice
The speaker evaluates the severe impact of the lower-than-expected Medicare Advantage payment increase proposal on UnitedHealth and the sudden depreciation in the stock.
* Does not constitute investment advice
Analyzes the disappointing revenue forecast and the impact of lower Medicare reimbursement rates on the stock's performance.
* Does not constitute investment advice
The speaker examines Cytokinetics stock in light of acquisition expectations in the sector and recent strong price movements.
* Does not constitute investment advice
The speaker assesses the growing investor interest in the healthcare sector and evaluates its positive divergence compared to the broader market.
* Does not constitute investment advice
The speaker analyzes Abivax as a potential target within the intense wave of mergers and acquisitions (M&A) in the pharmaceutical sector.
* Does not constitute investment advice
The speaker evaluates Structure Therapeutics among companies with high dealmaking potential in the biotech space.
* Does not constitute investment advice
